Skip to main
  1. Stocks
  2. Annovis Bio
  3. Forecast
ANVS

Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio (ANVS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annovis Bio is viewed positively because its flagship buntanetap has already shown positive Phase 2b cognitive data in mild Alzheimer's disease, while its pivotal Phase 3 trial is fully enrolled with 850 patients and top-line 6M data still expected in 1Q27. The company’s broader pipeline in Parkinson’s disease, Lewy body dementia, traumatic brain injury, and stroke adds multiple shots on goal, but the investment case is most dependent on a clinically meaningful 6M ADAS-Cog13 benefit and the potential for NDA or sNDA filings. Fundamentally, the setup is compelling because the unmet need in neurodegeneration is large, yet the balance sheet is tight with $2.8M cash at 3Q26-end, ~$12M quarterly burn, and likely future dilution.

Bears say

Annovis Bio is under pressure because its cash balance fell to $2.8M at 3Q26-end from $18.7M at 2Q26-end, leaving continued going-concern doubt even after a November 6 offering that raised about $19.6M net and added substantial dilution. The stock looks driven more by financing and listing risk than by fundamentals, with shares down 73% YTD to $0.93 and a market cap of about $57M, while the company also faces a continued-listing notice tied to market cap and stockholders’ equity below $50M. With management funding operations only through the March 2027 topline readout, the investment case remains highly dependent on a positive Ph3 result despite meaningful clinical, regulatory, and commercialization risk across buntanetap, ANVS405, and ANVS301.

Annovis Bio (ANVS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.

Annovis Bio (ANVS) Analyst Forecast & Price Prediction

Get the latest Annovis Bio (ANVS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Annovis Bio (ANVS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annovis Bio (ANVS) Forecast

Analysts have given Annovis Bio (ANVS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Annovis Bio (ANVS) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annovis Bio (ANVS)


Annovis Bio (ANVS) Analyst Forecast & Price Prediction

Get the latest Annovis Bio (ANVS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Annovis Bio (ANVS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ANVS stock data and trends